Enzo Biochem Inc. (NYSE:ENZ) shares traded down 4.4% during trading on Friday . The company traded as low as $6.36 and last traded at $6.37, with a volume of 180,364 shares trading hands. The stock had previously closed at $6.66.

Separately, Zacks Investment Research lowered shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday.

The stock has a market cap of $294.24 million and a price-to-earnings ratio of 16.65. The stock has a 50-day moving average price of $6.36 and a 200 day moving average price of $5.35.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Wednesday, June 8th. The company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02. The firm had revenue of $18.16 million for the quarter, compared to analyst estimates of $24.50 million. During the same period in the previous year, the business posted ($0.07) earnings per share. Equities research analysts predict that Enzo Biochem Inc. will post ($0.23) EPS for the current year.

Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.